Noctiva is a drug owned by Acerus Pharmaceuticals Usa Llc. It is protected by 6 US drug patents filed from 2017 to 2024. Out of these, 3 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 15, 2030. Details of Noctiva's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11419914 | Safe desmopressin administration |
Jun, 2030
(5 years from now) | Active |
| US12090190 | Safe desmopressin administration |
Jun, 2030
(5 years from now) | Active |
| US9539302 | Safe desmopressin administration |
Jun, 2030
(5 years from now) | Active |
| US7799761 | Pharmaceutical compositions including low dosages of desmopressin |
Sep, 2024
(2 months ago) |
Expired
|
| US7579321 | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(1 year, 7 months ago) |
Expired
|
| US7405203 | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(1 year, 7 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Noctiva's patents.
Latest Legal Activities on Noctiva's Patents
Given below is the list of recent legal activities going on the following patents of Noctiva.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jul, 2024 | US9539302 |
| Patent Issue Date Used in PTA Calculation Critical | 23 Aug, 2022 | US11419914 |
| Recordation of Patent Grant Mailed Critical | 23 Aug, 2022 | US11419914 |
| Email Notification Critical | 04 Aug, 2022 | US11419914 |
| Issue Notification Mailed Critical | 03 Aug, 2022 | US11419914 |
| Mailing Corrected Notice of Allowability | 15 Jul, 2022 | US11419914 |
| Email Notification Critical | 15 Jul, 2022 | US11419914 |
| Corrected Notice of Allowability | 12 Jul, 2022 | US11419914 |
| Pubs Case Remand to TC Critical | 11 Jul, 2022 | US11419914 |
| Dispatch to FDC | 06 Jul, 2022 | US11419914 |
FDA has granted several exclusivities to Noctiva. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Noctiva, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Noctiva.
Exclusivity Information
Noctiva holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Noctiva's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 03, 2020 |
Several oppositions have been filed on Noctiva's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Noctiva's generic, the next section provides detailed information on ongoing and past EP oppositions related to Noctiva patents.
Noctiva's Oppositions Filed in EPO
Noctiva has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 12, 2018, by Ferring B.V.. This opposition was filed on patent number EP10790053A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17168865A | Aug, 2020 | Ferring B.V. | Revoked |
| EP09796558A | May, 2019 | Ferring B.V. | Patent maintained as amended |
| EP10790053A | Mar, 2018 | Ferring B.V. | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Noctiva is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Noctiva's family patents as well as insights into ongoing legal events on those patents.
Noctiva's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Noctiva's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 15, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Noctiva Generic API suppliers:
Desmopressin Acetate is the generic name for the brand Noctiva. 24 different companies have already filed for the generic of Noctiva, with Abhai Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Noctiva's generic
Alternative Brands for Noctiva
Noctiva which is used for treating nocturia (frequent urination at night) in adults with nocturnal polyuria by administering intranasal desmopressin., has several other brand drugs using the same active ingredient (Desmopressin Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Ferring |
| |||
| Ferring Pharms Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Desmopressin Acetate, Noctiva's active ingredient. Check the complete list of approved generic manufacturers for Noctiva
About Noctiva
Noctiva is a drug owned by Acerus Pharmaceuticals Usa Llc. It is used for treating nocturia (frequent urination at night) in adults with nocturnal polyuria by administering intranasal desmopressin. Noctiva uses Desmopressin Acetate as an active ingredient. Noctiva was launched by Acerus Pharms in 2017.
Approval Date:
Noctiva was approved by FDA for market use on 03 March, 2017.
Active Ingredient:
Noctiva uses Desmopressin Acetate as the active ingredient. Check out other Drugs and Companies using Desmopressin Acetate ingredient
Treatment:
Noctiva is used for treating nocturia (frequent urination at night) in adults with nocturnal polyuria by administering intranasal desmopressin.
Dosage:
Noctiva is available in spray, metered form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.00166MG/SPRAY | SPRAY, METERED | Discontinued | NASAL |
| 0.00083MG/SPRAY | SPRAY, METERED | Discontinued | NASAL |